Development of immunomonitoring of antibody-dependent cellular cytotoxicity against neuroblastoma cells using whole blood
Development of immunomonitoring of antibody-dependent cellular cytotoxicity against neuroblastoma cells using whole blood
Neuroblastoma, a childhood tumour of neuroectodermal origin, accounts for 15 % of paediatric cancer deaths, which is often metastatic at diagnosis and despite aggressive therapies, it has poor long-term prognosis with high risk of recurrence. Monoclonal antibody (mAb) therapy targeting GD2, a disialoganglioside expressed on neuroblastoma, has shown promise in recent trials with natural killer cell (NK)-mediated antibody-dependent cellular cytotoxicity (ADCC) thought to be central to efficacy, although other immune effectors may be important. To further enhance therapy, immunomonitoring of patients is essential to elucidate the in vivo mechanisms of action and provides surrogate end points of efficacy for future clinical trials. Our aim was to establish a ‘real-time’ ex vivo whole-blood (WB) immunomonitoring strategy to perform within the logistical constraints such as limited sample volumes, anticoagulant effects, sample stability and shipping time. A fluorescent dye release assay measuring target cell lysis was coupled with flow cytometry to monitor specific effector response. Significant target cell lysis with anti-GD2 antibody (p < 0.05) was abrogated following NK depletion. NK up-regulation of CD107a and CD69 positively correlated with target cell lysis (r > 0.6). The ADCC activity of WB correlated with peripheral blood mononuclear cells (r > 0.95), although WB showed overall greater target cell lysis attributed to the combination of NK-mediated ADCC, CD16+ granulocyte degranulation and complement-dependent cytotoxicity. Response was maintained in heparinised samples stored for 24 h at room temperature, but not 4 °C. Critically, the assay showed good reproducibility (mean % CV < 6.4) and was successfully applied to primary neuroblastoma samples. As such, WB provides a resourceful analysis of multiple mechanisms for efficient end point monitoring to correlate immune modulation with clinical outcome.
immunotherapy, immunomonitoring, neuroblastoma, adcc, nk Cells
559-569
Chowdhury, Ferdousi
0af499d4-17c5-40cf-9426-0d509ab82595
Lode, Holger N.
9e453295-c91d-42bc-b7f0-c94ec7c954e3
Cragg, Mark S.
ec97f80e-f3c8-49b7-a960-20dff648b78c
Glennie, Martin J.
9f6f0eff-4560-48c2-80cd-0ec116110ded
Gray, Juliet C.
12d5e17c-97bb-4d6d-8fc4-3914b730ed42
June 2014
Chowdhury, Ferdousi
0af499d4-17c5-40cf-9426-0d509ab82595
Lode, Holger N.
9e453295-c91d-42bc-b7f0-c94ec7c954e3
Cragg, Mark S.
ec97f80e-f3c8-49b7-a960-20dff648b78c
Glennie, Martin J.
9f6f0eff-4560-48c2-80cd-0ec116110ded
Gray, Juliet C.
12d5e17c-97bb-4d6d-8fc4-3914b730ed42
Chowdhury, Ferdousi, Lode, Holger N., Cragg, Mark S., Glennie, Martin J. and Gray, Juliet C.
(2014)
Development of immunomonitoring of antibody-dependent cellular cytotoxicity against neuroblastoma cells using whole blood.
Cancer Immunology Immunotherapy, 63 (6), .
(doi:10.1007/s00262-014-1534-y).
(PMID:24658837)
Abstract
Neuroblastoma, a childhood tumour of neuroectodermal origin, accounts for 15 % of paediatric cancer deaths, which is often metastatic at diagnosis and despite aggressive therapies, it has poor long-term prognosis with high risk of recurrence. Monoclonal antibody (mAb) therapy targeting GD2, a disialoganglioside expressed on neuroblastoma, has shown promise in recent trials with natural killer cell (NK)-mediated antibody-dependent cellular cytotoxicity (ADCC) thought to be central to efficacy, although other immune effectors may be important. To further enhance therapy, immunomonitoring of patients is essential to elucidate the in vivo mechanisms of action and provides surrogate end points of efficacy for future clinical trials. Our aim was to establish a ‘real-time’ ex vivo whole-blood (WB) immunomonitoring strategy to perform within the logistical constraints such as limited sample volumes, anticoagulant effects, sample stability and shipping time. A fluorescent dye release assay measuring target cell lysis was coupled with flow cytometry to monitor specific effector response. Significant target cell lysis with anti-GD2 antibody (p < 0.05) was abrogated following NK depletion. NK up-regulation of CD107a and CD69 positively correlated with target cell lysis (r > 0.6). The ADCC activity of WB correlated with peripheral blood mononuclear cells (r > 0.95), although WB showed overall greater target cell lysis attributed to the combination of NK-mediated ADCC, CD16+ granulocyte degranulation and complement-dependent cytotoxicity. Response was maintained in heparinised samples stored for 24 h at room temperature, but not 4 °C. Critically, the assay showed good reproducibility (mean % CV < 6.4) and was successfully applied to primary neuroblastoma samples. As such, WB provides a resourceful analysis of multiple mechanisms for efficient end point monitoring to correlate immune modulation with clinical outcome.
This record has no associated files available for download.
More information
Accepted/In Press date: 7 March 2014
e-pub ahead of print date: 22 March 2014
Published date: June 2014
Keywords:
immunotherapy, immunomonitoring, neuroblastoma, adcc, nk Cells
Organisations:
Cancer Sciences
Identifiers
Local EPrints ID: 367349
URI: http://eprints.soton.ac.uk/id/eprint/367349
ISSN: 0340-7004
PURE UUID: 360ca9aa-85a9-4a3b-a65c-df41e1581825
Catalogue record
Date deposited: 28 Jul 2014 13:47
Last modified: 15 Mar 2024 03:16
Export record
Altmetrics
Contributors
Author:
Ferdousi Chowdhury
Author:
Holger N. Lode
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics